{"id":560802,"date":"2026-08-10T21:57:33","date_gmt":"2026-08-10T19:57:33","guid":{"rendered":"https:\/\/medizinonline.com\/?p=560802"},"modified":"2026-08-10T21:57:40","modified_gmt":"2026-08-10T19:57:40","slug":"la-revolucion-de-las-incretinas-en-la-cardiologia","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/la-revolucion-de-las-incretinas-en-la-cardiologia\/","title":{"rendered":"La revoluci\u00f3n de las incretinas en la cardiolog\u00eda"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>En el plazo de una d\u00e9cada, los mim\u00e9ticos de las incretinas han pasado de ser medicamentos hipoglucemiantes para la diabetes a convertirse en una de las clases de f\u00e1rmacos m\u00e1s din\u00e1micas de la medicina cardiovascular. Se ha demostrado que los agonistas del receptor del GLP-1 (GLP-1-RA) han demostrado reducir el riesgo de eventos cardiovasculares graves (MACE) y de hospitalizaciones por insuficiencia card\u00edaca, disminuyen la albuminuria y ralentizan la disminuci\u00f3n de la TFG estimada \u2014y esto, cada vez m\u00e1s, tambi\u00e9n fuera del contexto de la diabetes\u2014. Con el semaglutido oral, aparece por primera vez en escena un f\u00e1rmaco administrado por v\u00eda oral con beneficios cardiovasculares demostrados, acompa\u00f1ado de la primera base de datos a gran escala sobre la insuficiencia card\u00edaca en la diabetes tipo 2. Y en el horizonte ya se vislumbra la pr\u00f3xima generaci\u00f3n, con los agonistas triples como el retatrutido.     <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fla-revolucion-de-las-incretinas-en-la-cardiologia%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>En el plazo de una d\u00e9cada, los mim\u00e9ticos de las incretinas han pasado de ser medicamentos hipoglucemiantes para la diabetes a convertirse en una de las clases de f\u00e1rmacos m\u00e1s&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fla-revolucion-de-las-incretinas-en-la-cardiologia%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560803,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"De f\u00e1rmaco antidiab\u00e9tico a clase terap\u00e9utica cardiorrenal independiente","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11352,11475,11478,11377],"tags":[36517,95544,95542,17397,95543],"powerkit_post_featured":[],"class_list":["post-560802","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-cardiologia","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-nefrologia","tag-antidiabeticos-es","tag-cumbre","tag-incretina","tag-semaglutida-es","tag-sustain-6","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-20 01:35:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560802"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560802\/revisions"}],"predecessor-version":[{"id":560804,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560802\/revisions\/560804"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/560803"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560802"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}